Clinical Trial Update: Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy [Phase 3]

View source ↗

Summary

It reviews a Phase 3 trial comparing Insuman Comb 25 to Novolin 30R given twice daily for 24 weeks in Type 2 diabetes patients on insulin therapy. The study eva…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Insuman Comb 25 (insulin human)
• Novolin 30R (insulin regular)

Snippet

Sponsor: Sanofi | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED